Literature DB >> 9467629

Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting.

S E Kimmel1, M A Sekeres, J A Berlin, L R Goldberg, B L Strom.   

Abstract

A retrospective cohort study of patients undergoing cardiopulmonary bypass over 2 years at a single hospital was performed to determine the rate and predictors of attributing events to protamine and reporting them to a well-developed, hospital-based adverse drug reaction (ADR) program. Overall, 123 (12.9%) of 952 procedures were associated with an adverse event. Thirteen percent of these events were attributed to protamine in the medical record and 2.4% were reported to the ADR program. Only 19% of events attributed to protamine were reported. Even after excluding events with other measurable etiologies, the incidence of adverse events (2.6%) was still higher than that of attributed (0.8%) or reported (0.3%) events. Events that manifest as pulmonary hypertension occurred sooner after protamine, or were severe were significantly more likely to be attributed to protamine. These predictors demonstrated similar relationships with the probability of reporting events. Reliance on reporting of adverse events could not only underestimate the risk of these events, but might bias studies by identifying non-representative events.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467629     DOI: 10.1016/s0895-4356(97)00241-2

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  5 in total

1.  Can lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass?

Authors:  Mya S Baker; Julian R Skoyles; Frca Matt Shajar; Henry Skinner; David Richens; Ian M Mitchell
Journal:  J Extra Corpor Technol       Date:  2005-06

2.  Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.

Authors:  Andrew J Gale; Darlene J Elias; Patricia M Averell; Paul S Teirstein; Mitchell Buck; Steven D Brown; Zinaida Polonskaya; Andrew K Udit; M G Finn
Journal:  Thromb Res       Date:  2011-04-14       Impact factor: 3.944

3.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03

4.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

Review 5.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.